{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T15:15:25Z","timestamp":1790176525179,"version":"4.1.0"},"reference-count":54,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,25]],"date-time":"2025-01-25T00:00:00Z","timestamp":1737763200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalmicrobiologyandinfection.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Microbiology and Infection"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.cmi.2025.01.014","type":"journal-article","created":{"date-parts":[[2025,1,21]],"date-time":"2025-01-21T08:39:05Z","timestamp":1737448745000},"page":"958-970","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Association of nucleoside reverse transcriptase inhibitors with adverse perinatal outcomes in pregnant women living with HIV: systematic review and meta-analysis"],"prefix":"10.1016","volume":"31","author":[{"given":"Imogen","family":"Cowdell","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharina","family":"Beck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Molly","family":"Hey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clara","family":"Portwood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harriet","family":"Sexton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"Kumarendran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zoe","family":"Brandon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shona","family":"Kirtley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joris","family":"Hemelaar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cmi.2025.01.014_bib1","series-title":"The urgency of now: AIDS at a crossroads","year":"2024"},{"key":"10.1016\/j.cmi.2025.01.014_bib2","doi-asserted-by":"crossref","first-page":"e33","DOI":"10.1016\/S2352-3018(15)00207-6","article-title":"Perinatal outcomes associated with maternal HIV infection: a systematic review and meta-analysis","volume":"3","author":"Wedi","year":"2016","journal-title":"Lancet HIV"},{"key":"10.1016\/j.cmi.2025.01.014_bib3","series-title":"Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection. Recommendations for a public health approach","year":"2013"},{"key":"10.1016\/j.cmi.2025.01.014_bib4","first-page":"1409","article-title":"Adverse perinatal outcomes associated with HAART and monotherapy","volume":"36","author":"Portwood","year":"2022","journal-title":"AIDS"},{"key":"10.1016\/j.cmi.2025.01.014_bib5","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1038\/s43856-023-00331-8","article-title":"Adverse perinatal outcomes attributable to HIV in sub-Saharan Africa from 1990 to 2020: systematic review and meta-analyses","volume":"3","author":"Murray","year":"2023","journal-title":"Commun Med (Lond)"},{"key":"10.1016\/j.cmi.2025.01.014_bib6","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1016\/S0140-6736(23)00354-9","article-title":"Small vulnerable newborns-big potential for impact","volume":"401","author":"Ashorn","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.cmi.2025.01.014_bib7","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/S2352-4642(21)00311-4","article-title":"Global, regional, and national causes of under-5 mortality in 2000-19: an updated systematic analysis with implications for the Sustainable Development Goals","volume":"6","author":"Perin","year":"2022","journal-title":"Lancet Child Adolesc Health"},{"key":"10.1016\/j.cmi.2025.01.014_bib8","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1016\/S0140-6736(23)00878-4","article-title":"National, regional, and global estimates of preterm birth in 2020, with trends from 2010: a systematic analysis","volume":"402","author":"Ohuma","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.cmi.2025.01.014_bib9","article-title":"Estimates of burden and consequences of infants born small for gestational age in low and middle income countries with INTERGROWTH-21st standard: analysis of CHERG datasets","volume":"358","author":"Lee","year":"2017","journal-title":"BMJ"},{"key":"10.1016\/j.cmi.2025.01.014_bib10","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1016\/S0140-6736(23)01198-4","article-title":"National, regional, and global estimates of low birthweight in 2020, with trends from 2000: a systematic analysis","volume":"403","author":"Okwaraji","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.cmi.2025.01.014_bib11","doi-asserted-by":"crossref","first-page":"e195","DOI":"10.1016\/S2214-109X(21)00515-5","article-title":"Global, regional, and national trends in under-5 mortality between 1990 and 2019 with scenario-based projections until 2030: a systematic analysis by the UN Inter-agency Group for Child Mortality Estimation","volume":"10","author":"Sharrow","year":"2022","journal-title":"Lancet Glob Health"},{"key":"10.1016\/j.cmi.2025.01.014_bib12","series-title":"Consolidated guidelines on HIV prevention, testing, treatment, service delivery and monitoring: Recommendations for a public health approach","year":"2021"},{"key":"10.1016\/j.cmi.2025.01.014_bib13","unstructured":"Panel on Treatment of HIV in Pregnancy and Prevention of Perinatal Transmission. Recommendations for the Use of Antiretroviral Drugs During Pregnancy and Interventions to Reduce Perinatal HIV Transmission in the United States. Department of Health and Human Services. Available at https:\/\/clinicalinfo.hiv.gov\/en\/guidelines\/perinatal. (Accessed 11 February 2025)."},{"key":"10.1016\/j.cmi.2025.01.014_bib14","unstructured":"European AIDS Clinical Society. Treatment of pregnant women living with HIV or women considering pregnancy. EACS Guidelines. 2023;v12.0 Available at: https:\/\/www.eacsociety.org\/guidelines\/eacs-guidelines\/ (Accessed 11 February 2025)."},{"key":"10.1016\/j.cmi.2025.01.014_bib15","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1097\/QAD.0000000000002593","article-title":"Adverse perinatal outcomes associated with antiretroviral therapy regimens: systematic review and network meta-analysis","volume":"34","author":"Tshivuila-Matala","year":"2020","journal-title":"AIDS"},{"key":"10.1016\/j.cmi.2025.01.014_bib16","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1016\/S0140-6736(21)00314-7","volume":"397","author":"Lockman","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.cmi.2025.01.014_bib17","doi-asserted-by":"crossref","first-page":"e332","DOI":"10.1016\/S2352-3018(20)30050-3","article-title":"Dolutegravir versus efavirenz in women starting HIV therapy in late pregnancy (DolPHIN-2): an open-label, randomised controlled trial","volume":"7","author":"Kintu","year":"2020","journal-title":"Lancet HIV"},{"key":"10.1016\/j.cmi.2025.01.014_bib18","doi-asserted-by":"crossref","first-page":"e322","DOI":"10.1016\/S2352-3018(20)30038-2","article-title":"Raltegravir versus efavirenz in antiretroviral-naive pregnant women living with HIV (NICHD P1081): an open-label, randomised, controlled, phase 4 trial","volume":"7","author":"Jo\u00e3o","year":"2020","journal-title":"Lancet HIV"},{"key":"10.1016\/j.cmi.2025.01.014_bib19","article-title":"Comparative risk of adverse perinatal outcomes associated with classes of antiretroviral therapy in pregnant women living with HIV: systematic review and meta-analysis","volume":"11","author":"Beck","year":"2024","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.cmi.2025.01.014_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2022.101368","article-title":"Adverse perinatal outcomes associated with protease inhibitor-based antiretroviral therapy in pregnant women living with HIV: a systematic review and meta-analysis","volume":"46","author":"Cowdell","year":"2022","journal-title":"eClinicalMedicine"},{"key":"10.1016\/j.cmi.2025.01.014_bib21","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2017-019022","article-title":"Antiretroviral therapy for pregnant women living with HIV or hepatitis B: a systematic review and meta-analysis","volume":"7","author":"Siemieniuk","year":"2017","journal-title":"BMJ Open"},{"key":"10.1016\/j.cmi.2025.01.014_bib22","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/QAI.0000000000001359","article-title":"Safety of tenofovir disoproxil fumarate-based antiretroviral therapy regimens in pregnancy for HIV-infected women and their infants: a systematic review and meta-analysis","volume":"76","author":"Nachega","year":"2017","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.cmi.2025.01.014_bib23","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1111\/1471-0528.13542","article-title":"Association between in utero zidovudine exposure and nondefect adverse birth outcomes: analysis of prospectively collected data from the Antiretroviral Pregnancy Registry","volume":"123","author":"Vannappagari","year":"2016","journal-title":"BJOG"},{"key":"10.1016\/j.cmi.2025.01.014_bib24","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1097\/QAI.0000000000000465","article-title":"Abacavir and lamivudine exposures during pregnancy and non-defect adverse pregnancy outcomes: data from the antiretroviral pregnancy registry","volume":"68","author":"Vannappagari","year":"2015","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.cmi.2025.01.014_bib25","first-page":"6","article-title":"Pregnancy outcomes in pregnant women with HIV on tenofovir disoproxil fumarate (TDF) compared to tenofovir alafenamide (TAF)","volume":"4","author":"Thimm","year":"2022","journal-title":"J AIDS HIV Treat"},{"key":"10.1016\/j.cmi.2025.01.014_bib26","series-title":"Cochrane Handbook for Systematic Reviews of Interventions","year":"2019"},{"key":"10.1016\/j.cmi.2025.01.014_bib27","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.cmi.2025.01.014_bib28","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1097\/COH.0000000000000377","article-title":"Candidates for inclusion in a universal antiretroviral regimen: are lamivudine and emtricitabine interchangeable?","volume":"12","author":"Ford","year":"2017","journal-title":"Curr Opin HIV AIDS"},{"key":"10.1016\/j.cmi.2025.01.014_bib29","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1016\/S0140-6736(14)60932-6","article-title":"International standards for newborn weight, length, and head circumference by gestational age and sex: the Newborn Cross-Sectional Study of the INTERGROWTH-21st Project","volume":"384","author":"Villar","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.cmi.2025.01.014_bib30","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1097\/QAD.0000000000001673","article-title":"Emulating a target trial of antiretroviral therapy regimens started before conception and risk of adverse birth outcomes","volume":"32","author":"Caniglia","year":"2018","journal-title":"AIDS"},{"key":"10.1016\/j.cmi.2025.01.014_bib31","doi-asserted-by":"crossref","first-page":"40","DOI":"10.4103\/picr.PICR_74_19","article-title":"Treatment outcome of different antiretroviral drug regimens in HIV-positive pregnant women","volume":"12","author":"Chauhan","year":"2021","journal-title":"Perspect Clin Res"},{"key":"10.1016\/j.cmi.2025.01.014_bib32","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2018-027344","article-title":"Pregnancy outcome among HIV-infected women on different antiretroviral therapies in Ethiopia: a cohort study","volume":"9","author":"Ejigu","year":"2019","journal-title":"BMJ Open"},{"key":"10.1016\/j.cmi.2025.01.014_bib33","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1097\/QAD.0000000000002039","article-title":"Nucleoside reverse transcriptase inhibitor backbones and pregnancy outcomes","volume":"33","year":"2019","journal-title":"AIDS"},{"key":"10.1016\/j.cmi.2025.01.014_bib34","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1097\/QAI.0000000000002087","article-title":"Stillbirth in women living with HIV delivering in the United Kingdom and Ireland: 2007\u20132015","volume":"82","author":"Favarato","year":"2019","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.cmi.2025.01.014_bib35","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1097\/QAI.0000000000001640","article-title":"Brief report: abacavir\/lamivudine and tenofovir\/emtricitabine in pregnant women with HIV: laboratory and clinical outcomes in an observational national study","volume":"78","author":"Floridia","year":"2018","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.cmi.2025.01.014_bib36","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1001217","article-title":"Pregnancy and infant outcomes among HIV-infected women taking long-term ART with and without tenofovir in the DART trial","volume":"9","author":"Gibb","year":"2012","journal-title":"PLOS Med"},{"key":"10.1016\/j.cmi.2025.01.014_bib37","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1097\/QAD.0000000000003215","article-title":"Predictors of adverse pregnancy outcomes among Kenyan women with HIV on antiretroviral treatment in pregnancy","volume":"36","author":"Jiang","year":"2022","journal-title":"AIDS"},{"key":"10.1016\/j.cmi.2025.01.014_bib38","doi-asserted-by":"crossref","DOI":"10.7448\/IAS.18.1.19933","article-title":"Risk factors for pre-term birth in a Canadian cohort of HIV-positive women: role of ritonavir boosting?","volume":"18","author":"Kakkar","year":"2015","journal-title":"J Int AIDS Soc"},{"key":"10.1016\/j.cmi.2025.01.014_bib39","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s12884-016-0821-3","article-title":"Improved pregnancy outcomes with increasing antiretroviral coverage in South Africa","volume":"16","author":"Moodley","year":"2016","journal-title":"BMC Pregnancy Childbirth"},{"key":"10.1016\/j.cmi.2025.01.014_bib40","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1093\/infdis\/jix542","article-title":"Maternal tenofovir disoproxil fumarate use during pregnancy is not associated with adverse perinatal outcomes among HIV-infected East African women: a prospective study","volume":"216","author":"Pintye","year":"2017","journal-title":"J Infect Dis"},{"key":"10.1016\/j.cmi.2025.01.014_bib41","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1097\/QAI.0b013e3182a7adb2","article-title":"Infant growth outcomes after maternal tenofovir disoproxil fumarate use during pregnancy","volume":"64","author":"Ransom","year":"2013","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.cmi.2025.01.014_bib42","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1056\/NEJMoa1701666","article-title":"Birth outcomes for pregnant women with HIV using tenofovir-emtricitabine","volume":"378","author":"Rough","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cmi.2025.01.014_bib43","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s00431-019-03481-x","article-title":"Safety of tenofovir during pregnancy: early growth outcomes and hematologic side effects in HIV-exposed uninfected infants","volume":"179","author":"Seidel","year":"2020","journal-title":"Eur J Pediatr"},{"key":"10.1016\/j.cmi.2025.01.014_bib44","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1097\/QAD.0b013e328352d135","article-title":"Safety of tenofovir use during pregnancy: early growth outcomes in HIV-exposed uninfected infants","volume":"26","author":"Siberry","year":"2012","journal-title":"AIDS"},{"key":"10.1016\/j.cmi.2025.01.014_bib45","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1097\/QAI.0b013e31821d34d0","article-title":"Use of zidovudine-sparing HAART in pregnant HIV-infected women in Europe: 2000\u20132009","volume":"57","author":"Tariq","year":"2011","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.cmi.2025.01.014_bib46","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1186\/s12879-016-1400-y","article-title":"Maternal and foetal outcomes among 4118 women with HIV infection treated with lopinavir\/ritonavir during pregnancy: analysis of population-based surveillance data from the national study of HIV in pregnancy and childhood in the United Kingdom and Ireland","volume":"16","author":"Tookey","year":"2016","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.cmi.2025.01.014_bib47","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.3851\/IMP1909","article-title":"In utero exposure to tenofovir disoproxil fumarate does not impair growth and bone health in HIV-uninfected children born to HIV-infected mothers","volume":"16","author":"Vigan\u00f2","year":"2011","journal-title":"Antivir Ther"},{"key":"10.1016\/j.cmi.2025.01.014_bib48","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1097\/QAI.0000000000000847","article-title":"Reassuring birth outcomes with tenofovir\/emtricitabine\/efavirenz used for prevention of mother-to-child transmission of HIV in Botswana","volume":"71","author":"Zash","year":"2016","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.cmi.2025.01.014_bib49","doi-asserted-by":"crossref","DOI":"10.1001\/jamapediatrics.2017.2222","article-title":"Comparative safety of antiretroviral treatment regimens in pregnancy","volume":"171","author":"Zash","year":"2017","journal-title":"JAMA Pediatr"},{"key":"10.1016\/j.cmi.2025.01.014_bib50","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1056\/NEJMoa1511691","article-title":"Benefits and risks of antiretroviral therapy for perinatal HIV prevention","volume":"375","author":"Fowler","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cmi.2025.01.014_bib51","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2024.102532","article-title":"Perinatal outcomes associated with pre-exposure prophylaxis for HIV prevention during pregnancy: a systematic review and meta-analysis","volume":"70","author":"Erlwanger","year":"2024","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.cmi.2025.01.014_bib52","doi-asserted-by":"crossref","first-page":"e150","DOI":"10.1097\/AOG.0000000000002046","article-title":"Methods for estimating the due date","volume":"129","year":"2017","journal-title":"Obstet Gynecol"},{"issue":"Suppl 2","key":"10.1016\/j.cmi.2025.01.014_bib53","article-title":"Approaches to accelerating the study of new antiretrovirals in pregnancy","volume":"25","author":"Abrams","year":"2022","journal-title":"J Int AIDS Soc"},{"key":"10.1016\/j.cmi.2025.01.014_bib54","doi-asserted-by":"crossref","first-page":"e151","DOI":"10.1016\/S1473-3099(22)00687-9","article-title":"Understanding clinical outcome measures reported in HIV pregnancy studies involving antiretroviral-naive and antiretroviral-experienced women","volume":"23","author":"Eke","year":"2023","journal-title":"Lancet Infect Dis"}],"container-title":["Clinical Microbiology and Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X25000199?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X25000199?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,10]],"date-time":"2025-05-10T20:20:20Z","timestamp":1746908420000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1198743X25000199"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":54,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["S1198743X25000199"],"URL":"https:\/\/doi.org\/10.1016\/j.cmi.2025.01.014","relation":{},"ISSN":["1198-743X"],"issn-type":[{"value":"1198-743X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Association of nucleoside reverse transcriptase inhibitors with adverse perinatal outcomes in pregnant women living with HIV: systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Clinical Microbiology and Infection","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cmi.2025.01.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd on behalf of European Society of Clinical Microbiology and Infectious Diseases.","name":"copyright","label":"Copyright"}]}}